Skip to main content
. 2018 Jan 1;9(3):594–603. doi: 10.7150/jca.20461

Figure 4.

Figure 4

Kaplan-Meier estimates of the distant metastases-free survival and overall survival for stage III-IVB nasopharyngeal carcinoma patients treated with nimotuzumab and without nimotuzumab.